Literature DB >> 1409197

Sotalol-induced torsade de pointes: management with magnesium infusion.

M A Arstall1, J T Hii, R G Lehman, J D Horowitz.   

Abstract

A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation. Sotalol was initially well tolerated and reversion to sinus rhythm with sinus bradycardia occurred 4 weeks after initiation of therapy. Shortly thereafter, the patient developed recurrent syncope due to torsade de pointes. This was treated successfully with intravenous magnesium infusion and withdrawal of sotalol. Subsequently, the atrial fibrillation was adequately managed using amiodarone, with no recurrence of torsade de pointes. Development of bradycardia associated with reversion to sinus rhythm represents a potential cause of 'late' pro-arrhythmic effects of sotalol.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1409197      PMCID: PMC2399266          DOI: 10.1136/pgmj.68.798.289

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  10 in total

Review 1.  Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations?

Authors:  B Surawicz
Journal:  J Am Coll Cardiol       Date:  1989-07       Impact factor: 24.094

2.  Treatment of torsade de pointes with magnesium sulfate.

Authors:  D Tzivoni; S Banai; C Schuger; J Benhorin; A Keren; S Gottlieb; S Stern
Journal:  Circulation       Date:  1988-02       Impact factor: 29.690

3.  Torsade de pointes induced by sotalol despite therapeutic plasma sotalol concentrations.

Authors:  R Krapf; M Gertsch
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-15

4.  Sotalol-induced torsade de pointes.

Authors:  K H Kuck; K P Kunze; N Roewer; W Bleifeld
Journal:  Am Heart J       Date:  1984-01       Impact factor: 4.749

5.  [Hemiparesis and torsade de pointes under low-dose sotalol therapy].

Authors:  C Sieber; P Weiss; F Follath
Journal:  Schweiz Med Wochenschr       Date:  1990-09-22

6.  Depressant effect of magnesium on early afterdepolarizations and triggered activity induced by cesium, quinidine, and 4-aminopyridine in canine cardiac Purkinje fibers.

Authors:  S Kaseda; R F Gilmour; D P Zipes
Journal:  Am Heart J       Date:  1989-09       Impact factor: 4.749

7.  Torsade de pointes due to quinidine: observations in 31 patients.

Authors:  J L Bauman; R A Bauernfeind; J V Hoff; B Strasberg; S Swiryn; K M Rosen
Journal:  Am Heart J       Date:  1984-03       Impact factor: 4.749

8.  Sotalol, hypokalaemia, syncope, and torsade de pointes.

Authors:  J K McKibbin; W A Pocock; J B Barlow; R N Millar; I W Obel
Journal:  Br Heart J       Date:  1984-02

9.  Overdrive pacing as treatment of sotalol-induced ventricular tachyarrhythmias (torsade de pointes).

Authors:  K J Tötterman; H Turto; T Pellinen
Journal:  Acta Med Scand Suppl       Date:  1982

10.  Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.

Authors:  T A Mattioni; T A Zheutlin; J J Sarmiento; M Parker; M Lesch; R F Kehoe
Journal:  Ann Intern Med       Date:  1989-10-01       Impact factor: 25.391

  10 in total
  2 in total

Review 1.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 2.  Management strategies in cardiac surgery for postoperative atrial fibrillation: contemporary prophylaxis and futuristic anticoagulant possibilities.

Authors:  George Tokmaji; R Scott McClure; Tsuyoshi Kaneko; Sary F Aranki
Journal:  Cardiol Res Pract       Date:  2013-12-05       Impact factor: 1.866

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.